Healy John Stephen 4

What Happened John Stephen Healy, General Counsel and Corporate Secretary of Contineum Therapeutics, was granted a derivative award of 206,411 shares on 2026-01-30. The award is reported as an acquisition of derivative securities at $0.00 (i.e., an option/grant recorded as $0 in the Form 4). This is a grant of options/awards, not a cash purchase or sale, so there was no immediate cash transaction or change in beneficial ownership until options vest and are exercised.

Key Details

• Transaction date: 2026-01-30; transaction type: Award/Grant (derivative securities) reported at $0.00.
• Shares/units granted: 206,411 (options/award); reported as derivative securities.
• Shares owned after transaction: Not specified in the provided filing extract.
• Footnote: Options granted under the Issuer’s 2024 Equity Incentive Plan; they vest in equal monthly installments over 48 months, subject to continuous service.
• Filing timeliness: Report filed on 2026-01-30 for the 2026-01-30 transaction (no late-filing indication in the provided data).

Context This was an award of options (a derivative grant) rather than an immediate purchase of shares. Options vest over time, so the recipient must remain employed and then exercise vested options before acquiring shares. Such grants are common as compensation and retention tools and do not by themselves represent a buy/sell signal until options are exercised or shares are sold.